COX inhibitors(Cyclooxygenases inhibitors), P2Y12 receptor antagonists(Purinergic receptor P2Y12 antagonists), TBXA2R antagonists(Thromboxane A2 receptor antagonists)

Therapeutic Areas

Nervous System DiseasesCardiovascular DiseasesOther Diseases

Active Indication

Angina, StableOld myocardial infarctionNon ST segment elevation acute coronary syndrome+ [8]

Inactive Indication

AtherosclerosisBrain InfarctionEmbolism+ [2]

Originator Organization

Sanofi

Active Organization

Mylan NVSanofi-Aventis Australia Pty Ltd.Sanofi-Aventis Groupe SA

+ [3]

Inactive Organization

Teva Pharmaceuticals Europe BV

Bristol Myers Squibb Co.

Dong-A ST Co., Ltd.

+ [3]

Drug Highest PhaseApproved

First Approval Date

Singapore (01 Jan 2008),

Acute Coronary SyndromeAngina PectorisMyocardial Infarction+ [1]

Regulation-

Structure/Sequence

Molecular FormulaC25H26ClNO10S2

InChIKeyUSKPQBRNXDJQGX-CKUXDGONSA-N

CAS Registry937818-61-6

Clinical Trials associated with Clopidogrel Bisulfate/Aspirin

CTR20250513

/ Active, not recruitingNot Applicable

氯吡格雷阿司匹林片生物等效性试验

[Translation] Bioequivalence study of clopidogrel and aspirin tablets

主要研究目的评价中国健康成年受试者空腹及餐后条件下单次单剂量口服氯吡格雷阿司匹林片受试制剂【规格：每片含硫酸氢氯吡格雷75mg（以氯吡格雷计）与阿司匹林100mg，申办者：甘正（海南）生物药业有限公司】和参比制剂【商品名：多立维®，规格：每片含硫酸氢氯吡格雷75mg（以氯吡格雷计）与阿司匹林100mg，持证商：Sanofi K.K.】后的药代动力学特点和生物等效性。次要研究目的研究氯吡格雷阿司匹林片受试制剂【规格：每片含硫酸氢氯吡格雷75mg（以氯吡格雷计）与阿司匹林100mg】和参比制剂【商品名：多立维®，规格：每片含硫酸氢氯吡格雷75mg（以氯吡格雷计）与阿司匹林100mg】在中国健康成年受试者中的安全性。

[Translation]

Main study objectives To evaluate the pharmacokinetic characteristics and bioequivalence of the test formulation of clopidogrel aspirin tablets [Specification: each tablet contains 75 mg of clopidogrel bisulfate (calculated as clopidogrel) and 100 mg of aspirin, applicant: Ganzheng (Hainan) Biopharmaceutical Co., Ltd.] and the reference formulation [trade name: Duoliwei®, specification: each tablet contains 75 mg of clopidogrel bisulfate (calculated as clopidogrel) and 100 mg of aspirin, licensee: Sanofi K.K.] in healthy Chinese adult subjects after a single oral dose under fasting and postprandial conditions. Secondary study objectives To study the safety of the test formulation of clopidogrel aspirin tablets [Specification: each tablet contains 75 mg of clopidogrel bisulfate (calculated as clopidogrel) and 100 mg of aspirin] and the reference formulation [trade name: Duoliwei®, specification: each tablet contains 75 mg of clopidogrel bisulfate (calculated as clopidogrel) and 100 mg of aspirin] in healthy Chinese adult subjects.

Start Date27 Feb 2025

Sponsor / Collaborator

Hainan Zhongyan Pharmaceutical Technology Co., Ltd.

CTR20250294

/ Active, not recruitingNot Applicable

氯吡格雷阿司匹林片在健康人群中的生物等效性试验

[Translation] Bioequivalence study of clopidogrel and aspirin tablets in healthy people

主要研究目的：按有关生物等效性试验的规定，选择サノフィ株式会社为持证商的硫酸氢氯吡格雷阿司匹林片（商品名：ComPlavin，规格：75mg/100mg）为参比制剂，对江苏吉贝尔药业股份有限公司生产并提供的受试制剂氯吡格雷阿司匹林片（规格：75mg/100mg）进行空腹和餐后给药人体生物等效性预试验，比较两种制剂在中国健康志愿者体内的药代动力学行为，评估两种制剂在空腹和餐后给药条件下生物等效性的可能性。次要研究目的：观察健康志愿受试者口服受试制剂氯吡格雷阿司匹林片（规格：75mg/100mg）和参比制剂硫酸氢氯吡格雷阿司匹林片（商品名：ComPlavin，规格：75mg/100mg）的安全性。

[Translation]

Main research purpose: According to the relevant provisions of bioequivalence test, clopidogrel aspirin tablets (trade name: ComPlavin, specification: 75mg/100mg) of Sanofi Co., Ltd. as the licensee was selected as the reference preparation, and the test preparation clopidogrel aspirin tablets (specification: 75mg/100mg) produced and provided by Jiangsu Jibei Pharmaceutical Co., Ltd. was conducted on the fasting and fed human bioequivalence preliminary test, and the pharmacokinetic behavior of the two preparations in healthy Chinese volunteers was compared, and the possibility of bioequivalence of the two preparations under fasting and fed conditions was evaluated. Secondary research purpose: To observe the safety of oral administration of the test preparation clopidogrel aspirin tablets (specification: 75mg/100mg) and the reference preparation clopidogrel aspirin tablets (trade name: ComPlavin, specification: 75mg/100mg) by healthy volunteers.

Start Date21 Feb 2025

Sponsor / Collaborator

Jiangsu Jibeier Pharmaceutical Co. Ltd.

CTR20243755

/ CompletedNot Applicable

氯吡格雷阿司匹林片生物等效性试验

[Translation] Bioequivalence study of clopidogrel and aspirin tablets

主要研究目的评价中国健康成年受试者空腹及餐后条件下单次单剂量口服氯吡格雷阿司匹林片受试制剂（规格：75mg/100mg，申办者：湖南尚众合生物医药有限公司）和参比制剂（商品名：多立维®，规格：75mg/100mg，持证商：Sanofi K.K.）后的药代动力学特点和生物等效性。次要研究目的研究氯吡格雷阿司匹林片受试制剂（规格：75mg/100mg）和参比制剂（商品名：多立维®，规格：75mg/100mg）在中国健康成年受试者中的安全性。

[Translation]

Main study objectives To evaluate the pharmacokinetic characteristics and bioequivalence of a single oral dose of clopidogrel aspirin tablets (specification: 75mg/100mg, applicant: Hunan Shangzhonghe Biopharmaceutical Co., Ltd.) and a reference preparation (trade name: Duoliwei®, specification: 75mg/100mg, licensee: Sanofi K.K.) in healthy Chinese adult subjects under fasting and postprandial conditions. Secondary study objectives To study the safety of clopidogrel aspirin tablets (specification: 75mg/100mg) and a reference preparation (trade name: Duoliwei®, specification: 75mg/100mg) in healthy Chinese adult subjects.

Start Date18 Nov 2024

Sponsor / Collaborator

Hunan Shangzhonghe Biopharmaceutical Co., Ltd.

100 Clinical Results associated with Clopidogrel Bisulfate/Aspirin

100 Translational Medicine associated with Clopidogrel Bisulfate/Aspirin

100 Patents (Medical) associated with Clopidogrel Bisulfate/Aspirin

Literatures (Medical) associated with Clopidogrel Bisulfate/Aspirin

01 Jun 2020·Advances in therapyQ3 · MEDICINE

Implementation of a Reference-Scaled Average Bioequivalence Approach for Highly Variable Acetylsalicylic Acid in Fixed-Dose Combination with Clopidogrel Versus Enteric Aspirin in Chinese Subjects Under Fasting Conditions: A Phase 1, Open-Label, Randomized, Crossover Study

Q3 · MEDICINE

Article

Author: Xie, Fang ; Wang, Lu ; Ming, Jeffrey E ; Zhang, Linlin ; Di, Yujing ; Ping, Chuan ; Yin, Huiqiu ; Li, Yi ; Yang, Na ; Kong, Fangyuan ; Hou, Jie ; Guo, Tingting

INTRODUCTION:

Dual antiplatelet therapy, aspirin and a P2Y₁₂ inhibitor, is recommended to prevent thrombotic complications of acute coronary syndrome. Clopidogrel plus acetylsalicylic acid combination is the most commonly used dual antiplatelet therapy recommended by international guidelines and in Chinese clinical practice. Poor adherence to dual antiplatelet therapy or premature interruption of dual antiplatelet therapy is an important contributor to cardiovascular mortality and lethal cardiovascular events. Clopidogrel + acetylsalicylic acid fixed-dose combination enhances adherence to dual antiplatelet therapy. Herein, we aimed to evaluate bioequivalence of acetylsalicylic acid and clopidogrel in fixed-dose combination compared with simultaneous administration of their individual formulations in healthy Chinese subjects under fasting conditions.

METHODS:

This was a randomized, single-center, open-label, three-sequence, three-period, two-treatment, crossover study with a washout period of 10 days conducted in healthy Chinese volunteers. Subjects were randomized to receive Co-Plavix^® (test formulation- fixed-dose combination of 100 mg acetylsalicylic acid and 75 mg clopidogrel) once and reference formulations (coadministration of individual formulations of 100 mg acetylsalicylic acid and 75 mg clopidogrel) twice during the study period. Pharmacokinetic parameters were analyzed for acetylsalicylic acid, its metabolite salicylic acid, clopidogrel, and its metabolite SR26334. As acetylsalicylic acid shows high intrasubject variability, the reference-scaled average bioequivalence (RSABE) approach was implemented for acetylsalicylic acid analysis, while bioequivalence of clopidogrel was assessed using the average bioequivalence method. Point ratios and confidence intervals (CIs) for AUC, AUC_last, and C_max for acetylsalicylic acid and clopidogrel were calculated.

RESULTS:

In total, 171 healthy subjects were enrolled in this study. Subjects were randomized and 170 subjects were treated with test or reference formulation; 164 subjects completed the study. Regarding acetylsalicylic acid exposure, as reference within-subject standard deviation (SD_W) was at least 0.294 for acetylsalicylic acid C_max, AUC_last, and AUC, the RSABE analysis method was used to assess bioequivalence for all three parameters. The point estimates were within the 0.80-1.25 range (1.19, 1.09, and 1.04, respectively), and upper one-sided 95% CIs of scaled average bioequivalence metric were at most 0 (- 0.30, - 0.14, and - 0.10, respectively). Thus, bioequivalence was demonstrated with acetylsalicylic acid. Bioequivalence was also achieved with clopidogrel as the 90% CIs for geometric mean ratios of clopidogrel C_max, AUC_last, and AUC were within the bioequivalence range (0.80-1.25).

CONCLUSION:

Application of the reference-scaled average bioequivalence approach to evaluate bioequivalence of acetylsalicylic acid in Chinese male and female healthy volunteers under fasting conditions demonstrated bioequivalence of test and reference formulations.

TRIAL REGISTRATION:

CTR20181695.

17 Feb 2017·PlateletsQ3 · MEDICINE

Pharmacodynamic effects of a new fixed-dose clopidogrel–aspirin combination compared with separate administration of clopidogrel and aspirin in patients treated with coronary stents: The ACCEL-COMBO trial

Q3 · MEDICINE

Article

Author: Ahn, Jong-Hwa ; Hwang, Jin-Yong ; Kwak, Choong Hwan ; Tantry, Udaya S. ; Kim, Kyehwan ; Kang, Min Gyu ; Park, Jeong Rang ; Park, Yongwhi ; Gurbel, Paul A. ; Jeong, Young-Hoon ; Koh, Jin-Sin ; Park, Hyun Woong ; Jang, Jeong Yoon ; Hwang, Seok-Jae

Dual antiplatelet therapy (DAPT) with clopidogrel and aspirin is a widely prescribed regimen to prevent ischemic events in patients undergoing percutaneous coronary intervention (PCI). A fixed-dose combination (FDC) capsule (HCP0911) has been developed to provide dosing convenience and improve adherence. We compared the antiplatelet effects of single daily dose HCP0911 with separate treatment with daily 75 mg clopidogrel plus 100 mg aspirin. This was a randomized, open-label, two-period, crossover, non-inferiority study conducted in stented patients who had been treated for at least 6 months with clopidogrel and aspirin. Thirty patients were randomly assigned to receive either daily 75 mg clopidogrel plus 100 mg aspirin treatment or HCP0911 for 2 weeks and then were crossed over to the other treatment for 2 weeks. Pharmacodynamic effects were measured with VerifyNow, light transmittance aggregometry (LTA), and thromboelastography (TEG^®). The primary endpoint was P2Y12 Reaction Units (PRU) measured by VerifyNow. PRUs during treatment with HCP0911 were not inferior to those during separate treatment (202 ± 52 vs. 207 ± 60 PRU; mean difference, -5 PRU; 90% confidence interval of difference, -23 to 13 PRU; P for non-inferiority = 0.015 for predetermined limit). "BASE" and Aspirin Reaction Units by VerifyNow did not differ between the two treatments. During each treatment, there were no differences in maximal and final platelet aggregations by LTA (all P values ≥0.822) and TEG^® measurements. In conclusion, in stented patients, the antiplatelet effect of a fixed-dose clopidogrel-aspirin combination, HCP0911, was not inferior to separate administration of clopidogrel and aspirin.

01 Jan 2013·Current Pharmaceutical Analysis

Analysis of Purity of Clopidogrel and Acetylsalicylic Acid in Combined Oral Dosage Forms

Author: Punie, Xavier ; Van Nyen, Geert ; Van Schepdael, Ann ; Adams, Erwin ; Dhulipalla, Rajya Lakshmi ; Kahsay, Getu

The quality of clopidogrel (CLP) and acetylsalicylic acid (ASA) combination dosage forms was evaluated for their content, impurities, and drug release.An enantiospecific (chiral) method for the quantification of the R-enantiomer of CLP and an achiral method for the determination of the content of CLP and ASA and their impurities were used.The following stationary phases were used: a CHIRALCEL OJ column (250 mm × 4.6 mm, 10 μm) for the quantification of the R-enantiomer and a Luna C18 column (150 mm × 4.6 mm, 3 μm) for the determination of the content of CLP, ASA, and their impurities and for the follow up of the release.Ten com. batches corresponding to 10 different marketed drugs containing CLP and ASA combination dosage forms (tablets and capsules) were analyzed.Although no monograph is available for combined dosage forms of CLP and ASA, most of the samples comply with the USP specification for content and related substances of the individual monographs.However, there are notable differences between samples examined in terms of in vitro drug release.

News (Medical) associated with Clopidogrel Bisulfate/Aspirin

11 Nov 2022

·www.ema.europa.eu

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 7-10 November 2022

Four new medicines recommended for approval EMA’s human medicines committee ( CHMP ) recommended four medicines for approval at its November 2022 meeting. The CHMP recommended authorising the COVID-19 vaccine VidPrevtynBeta (COVID-19 vaccine (recombinant, adjuvanted)) as a booster in adults previously vaccinated with an mRNA or adenoviral vector COVID-19 vaccine. It is the seventh vaccine recommended in the European Union (EU) for protecting against COVID-19 and, together with the vaccines already authorised, will support vaccination campaigns in EU Member States during the pandemic. See more information in the news announcement in the grid below. The committee adopted a positive opinion for a biosimilar medicine , Kauliv (teriparatide), for the treatment of osteoporosis, a health condition that weakens bones, making them fragile and more likely to break. A generic medicine , Pirfenidone Viatris (pirfenidone), received a positive opinion for the treatment of idiopathic pulmonary fibrosis, a chronic and progressive condition in which the lungs become scarred and breathing becomes increasingly difficult. The CHMP adopted a positive opinion for a generic medicine , Sugammadex Amomed (sugammadex), intended for the reversal of neuromuscular blockade induced by rocuronium in adults and children or vecuronium in adults. Rocuronium and vecuronium are muscle relaxants used during some types of surgeries. Sugammadex is used to speed up the recovery from the effects of the muscle relaxant. Recommendations on extensions of therapeutic indication for 11 medicines The committee recommended 11 extensions of indication for medicines that are already authorised in the EU: Ceprotin , Comirnaty , DuoPlavin , Dupixent , Enhertu , Eylea , Imfinzi , Iscover , Lynparza , Plavix and Xofluza . Withdrawals of applications Two applications for marketing authorisation were withdrawn: Orepaxam * for the treatment of pulmonary arterial hypertension, and Febseltiq * for the treatment of cholangiocarcinoma (cancer of the bile ducts). Two applications for extensions of therapeutic indications were withdrawn: Gavreto for the treatment of certain types of thyroid cancer, and Ilaris for the treatment of Schnitzler syndrome, a rare inflammatory disease causing long-term urticaria, recurrent fever, bone and joint pain, and swollen lymph nodes. Question-and-answer documents on the withdrawals are available in the grid below. COVID-19 update The committee recommended extending the use of COVID-19 vaccine Comirnaty targeting the original strain and Omicron subvariants BA.4 and BA.5 in children between 5 to 11 years of age. An overview of all the COVID-19 vaccines authorised in the EU is available on EMA’s website. Safety update The CHMP endorsed the measures recommended by the Pharmacovigilance Risk Assessment Committee ( PRAC ) to minimise the risk of serious side effects with Janus kinase (JAK) inhibitors used to treat several chronic inflammatory disorders. These side effects include cardiovascular conditions, blood clots, cancer and serious infections. This recommendation is the outcome of an article 20 referral procedure, which is triggered for medicines that have been authorised via the centralised procedure in case ofquality, safety or efficacy issues. A public health communication on this referral is available in the grid below. Agenda and minutes The agenda of the November 2022 CHMP meeting is published on EMA's website. Minutes of the October 2022 CHMP meeting will be published in the coming weeks. CHMP statistics Key figures from the November 2022 CHMP meeting are represented in the graphic below. *This product was designated as an orphan medicine during its development. Orphan designations are reviewed by EMA's Committee for Orphan Medicinal Products ( COMP ) at the time of approval to determine whether the information available to date allows maintaining the medicine’s orphan status and granting the medicine ten years of market exclusivity . Positive recommendation on new medicines Name of medicine VidPrevtyn Beta International non-proprietary name (INN) COVID-19 vaccine (recombinant, adjuvanted) Marketing-authorisation applicant Sanofi Pasteur Therapeutic indication VidPrevtyn Beta is indicated as a booster for active immunisation to prevent COVID-19 in adults who have previously received a mRNA or adenoviral vector COVID-19 vaccine More information VidPrevtyn Beta: Pending EC decision News announcement: EMA recommends approval of VidPrevtyn Beta as a COVID 19 booster vaccine Positive recommendation on new biosimilar medicine Name of medicine Kauliv INN teriparatide Marketing-authorisation applicant Strides Pharma Cyprus Therapeutic indication Treatment of osteoporosis More information Kauliv: Pending EC decision Positive recommendations on new generic medicines Name of medicine Pirfenidone Viatris INN pirfenidone Marketing-authorisation applicant Viatris Limited Therapeutic indication Treatment of idiopathic pulmonary fibrosis More information Pirfenidone Viatris: Pending EC decision Name of medicine Sugammadex Amomed INN sugammadex Marketing-authorisation applicant AOP Orphan Pharmaceuticals GmbH Therapeutic indication Reversal of neuromuscular blockade induced by rocuronium or vecuronium More information Sugammadex Amomed: Pending EC decision Positive recommendations on extensions of indications Name of medicine Ceprotin INN human protein C Marketing-authorisation holder Takeda Manufacturing Austria AG More information Ceprotin: Pending EC decision Name of medicine Comirnaty INN tozinameran Marketing-authorisation holder BioNTech Manufacturing GmbH More information Comirnaty: Pending EC decision Name of medicine DuoPlavin INN clopidogrel / acetylsalicylic acid Marketing-authorisationholder Sanofi-aventis groupe More information DuoPlavin: Pending EC decision Name of medicine Dupixent INN dupilumab Marketing-authorisation holder Sanofi-aventis groupe More information Dupixent: Pending EC decision Name of medicine Enhertu INN trastuzumab deruxtecan Marketing-authorisation holder Daiichi Sankyo Europe GmbH More information Enhertu: Pending EC decision Name of medicine Eylea INN aflibercept Marketing-authorisation holder Bayer AG More information Eylea: Pending EC decision Name of medicine Imfinzi INN durvalumab Marketing-authorisation holder AstraZeneca AB More information Imfinzi: Pending EC decision Name of medicine Iscover INN clopidogrel Marketing-authorisationholder Sanofi-aventis groupe More information Iscover: Pending EC decision Name of medicine Lynparza INN olaparib Marketing-authorisationholder AstraZeneca AB More information Lynparza: Pending EC decision Name of medicine Plavix INN clopidogrel Marketing-authorisationholder Sanofi-aventis groupe More information Plavix: Pending EC decision Name of medicine Xofluza INN baloxavir marboxil Marketing-authorisationholder Roche Registration GmbH More information Xofluza: Pending EC decision Withdrawal of initial marketing authorisation application Name of medicine Febseltiq INN infigratinib Marketing-authorisation applicant Helsinn Birex Pharmaceuticals Limited More information Febseltiq: Withdrawn application Name of medicine Orepaxam INN treprostinil diolamine Marketing-authorisationapplicant Ferrer Internacional S.A. More information Orepaxam: Withdrawn application Withdrawals of post-authorisation marketing authorisation applications Name of medicine Gavreto INN pralsetinib More information Gavreto: Withdrawn application Name of medicine Ilaris INN canakinumab More information Ilaris: Withdrawn application Conclusion of referral Name of medicine Janus kinase (JAK) inhibitors More information Janus Kinase inhibitors (JAKi) Other updates List item Scientific advice and protocol assistance adopted during the CHMP meeting 7-10 November 2022 (PDF/246.92 KB) (new) Adopted First published: 11/11/2022 EMA/CHMP/SAWP/872304/2022 List item Start of Union reviews adopted during the CHMP meeting of 7-10 November 2022 (PDF/106.5 KB) (new) Adopted First published: 11/11/2022 EMA/846051/2022

VaccineDrug ApprovalOrphan Drug

100 Deals associated with Clopidogrel Bisulfate/Aspirin

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	B01AC30	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Angina, Stable	Japan	Sanofi KK	20 Sep 2013
Old myocardial infarction	Japan	Sanofi KK	20 Sep 2013
Non ST segment elevation acute coronary syndrome	European Union	Sanofi Winthrop Industrie SA	14 Mar 2010
Non ST segment elevation acute coronary syndrome	Iceland	Sanofi Winthrop Industrie SA	14 Mar 2010
Non ST segment elevation acute coronary syndrome	Liechtenstein	Sanofi Winthrop Industrie SA	14 Mar 2010
Non ST segment elevation acute coronary syndrome	Norway	Sanofi Winthrop Industrie SA	14 Mar 2010
Non-Q wave myocardial infarction	European Union	Sanofi Winthrop Industrie SA	14 Mar 2010
Non-Q wave myocardial infarction	Iceland	Sanofi Winthrop Industrie SA	14 Mar 2010
Non-Q wave myocardial infarction	Liechtenstein	Sanofi Winthrop Industrie SA	14 Mar 2010
Non-Q wave myocardial infarction	Norway	Sanofi Winthrop Industrie SA	14 Mar 2010
Angina, Unstable	Australia	Sanofi-Aventis Australia Pty Ltd.	24 Sep 2009
Non-St Elevated Myocardial Infarction	Australia	Sanofi-Aventis Australia Pty Ltd.	24 Sep 2009
ST Elevation Myocardial Infarction	Australia	Sanofi-Aventis Australia Pty Ltd.	24 Sep 2009
Acute Coronary Syndrome	Singapore	Sanofi	01 Jan 2008
Angina Pectoris	Singapore	Sanofi	01 Jan 2008
Myocardial Infarction	Singapore	Sanofi	01 Jan 2008
Thrombosis	Singapore	Sanofi	01 Jan 2008

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Brain Infarction	Phase 3	Australia	Bristol Myers Squibb Co.	01 Feb 2002
Brain Infarction	Phase 3	Australia	Sanofi	01 Feb 2002
Brain Infarction	Phase 3	France	Sanofi	01 Feb 2002
Brain Infarction	Phase 3	France	Bristol Myers Squibb Co.	01 Feb 2002
Embolism	Phase 3	Australia	Sanofi	01 Feb 2002
Embolism	Phase 3	Australia	Bristol Myers Squibb Co.	01 Feb 2002
Embolism	Phase 3	France	Sanofi	01 Feb 2002
Embolism	Phase 3	France	Bristol Myers Squibb Co.	01 Feb 2002
Ischemic Attack, Transient	Phase 3	Australia	Sanofi	01 Feb 2002
Ischemic Attack, Transient	Phase 3	Australia	Bristol Myers Squibb Co.	01 Feb 2002

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis